Randomized Phase 3 Study of Aprepitant Versus Placebo in Chinese Advanced Non-small Cell Lung Cancer Who Received Highly Emetogenic Chemotherapy View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2014-2017

ABSTRACT

Aprepitant is an oral neurokinin-1(NK-1) antagonist which is widely used for the prevention of chemotherapy-induced nausea and vomiting(CINV), it is metabolized by CYP34A, however, up to now it was still unknown the CINV control rate of aprepitant in Chinese non-small cell lung cancer(NSCLC) patients, we hypothesis that CYP3A4 and NK-1 polymorphism would influence aprepitant plasma concentration, which may lead to the individual difference of CINV control rate. Detailed Description Patients pathologic diagnosed of advanced non-small cell lung cancer, according to NCCN non-small cell lung cancer guide line(2014 V2),the patient should receive standard platinum based chemotherapy, are randomized divided into two groups, aprepitant group and placebo group. In aprepitant group, patients would receive aprepitant 125 mg at day1, then 80 mg at day2 and day3. In placebo group, patients would receive placebo from day1 to day3. In both group, dexamethasone and 5-HT inhibitor palonosetron were give at the same dose. During the treatment, any grade of nausea and vomiting should be recorded in order to evaluate the complete response rate of CINV, other side-effects should be recorded. In aprepitant group, plasma should be taken for the analyze of plasma concentration, gene polymorphism of CYP3A4 and NK-1 should be analyzed for all the patients who received aprepitant if possible. More... »

URL

https://clinicaltrials.gov/show/NCT02161991

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Aprepitant is an oral neurokinin-1(NK-1) antagonist which is widely used for the prevention of chemotherapy-induced nausea and vomiting(CINV), it is metabolized by CYP34A, however, up to now it was still unknown the CINV control rate of aprepitant in Chinese non-small cell lung cancer(NSCLC) patients, we hypothesis that CYP3A4 and NK-1 polymorphism would influence aprepitant plasma concentration, which may lead to the individual difference of CINV control rate.\n\nDetailed Description\nPatients pathologic diagnosed of advanced non-small cell lung cancer, according to NCCN non-small cell lung cancer guide line(2014 V2),the patient should receive standard platinum based chemotherapy, are randomized divided into two groups, aprepitant group and placebo group. In aprepitant group, patients would receive aprepitant 125 mg at day1, then 80 mg at day2 and day3. In placebo group, patients would receive placebo from day1 to day3. In both group, dexamethasone and 5-HT inhibitor palonosetron were give at the same dose. During the treatment, any grade of nausea and vomiting should be recorded in order to evaluate the complete response rate of CINV, other side-effects should be recorded. In aprepitant group, plasma should be taken for the analyze of plasma concentration, gene polymorphism of CYP3A4 and NK-1 should be analyzed for all the patients who received aprepitant if possible.", 
    "endDate": "2017-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT02161991", 
    "keywords": [
      "aprepitant", 
      "advanced non-small cell lung cancer", 
      "neurokinin", 
      "antagonist", 
      "prevention", 
      "chemotherapy-induced nausea", 
      "Non-Small-Cell Lung Carcinoma", 
      "patient", 
      "CYP3A4", 
      "Genetic Polymorphism", 
      "plasma concentration", 
      "Individuality", 
      "non small cell lung cancer", 
      "V2", 
      "platinum-based chemotherapy", 
      "placebo group", 
      "placebo", 
      "dexamethasone", 
      "inhibitor", 
      "same dose", 
      "grade", 
      "nausea", 
      "vomiting", 
      "complete response rate", 
      "side effect", 
      "plasma", 
      "gene polymorphism"
    ], 
    "name": "Randomized Phase 3 Study of Aprepitant Versus Placebo in Chinese Advanced Non-small Cell Lung Cancer Who Received Highly Emetogenic Chemotherapy", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT02161991"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00016.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.410622.3", 
        "type": "Organization"
      }
    ], 
    "startDate": "2014-06-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1007/s00520-013-2043-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004661795", 
          "https://doi.org/10.1007/s00520-013-2043-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bbmt.2012.07.019", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019208035"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.39.5558", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025698429"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ctrv.2012.09.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038011325"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT02161991"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT02161991'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT02161991'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT02161991'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT02161991'


 

This table displays all metadata directly associated to this object as RDF triples.

59 TRIPLES      16 PREDICATES      46 URIs      36 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT02161991 schema:about anzsrc-for:3142
2 schema:description Aprepitant is an oral neurokinin-1(NK-1) antagonist which is widely used for the prevention of chemotherapy-induced nausea and vomiting(CINV), it is metabolized by CYP34A, however, up to now it was still unknown the CINV control rate of aprepitant in Chinese non-small cell lung cancer(NSCLC) patients, we hypothesis that CYP3A4 and NK-1 polymorphism would influence aprepitant plasma concentration, which may lead to the individual difference of CINV control rate. Detailed Description Patients pathologic diagnosed of advanced non-small cell lung cancer, according to NCCN non-small cell lung cancer guide line(2014 V2),the patient should receive standard platinum based chemotherapy, are randomized divided into two groups, aprepitant group and placebo group. In aprepitant group, patients would receive aprepitant 125 mg at day1, then 80 mg at day2 and day3. In placebo group, patients would receive placebo from day1 to day3. In both group, dexamethasone and 5-HT inhibitor palonosetron were give at the same dose. During the treatment, any grade of nausea and vomiting should be recorded in order to evaluate the complete response rate of CINV, other side-effects should be recorded. In aprepitant group, plasma should be taken for the analyze of plasma concentration, gene polymorphism of CYP3A4 and NK-1 should be analyzed for all the patients who received aprepitant if possible.
3 schema:endDate 2017-12-01T00:00:00Z
4 schema:keywords CYP3A4
5 Genetic Polymorphism
6 Individuality
7 Non-Small-Cell Lung Carcinoma
8 V2
9 advanced non-small cell lung cancer
10 antagonist
11 aprepitant
12 chemotherapy-induced nausea
13 complete response rate
14 dexamethasone
15 gene polymorphism
16 grade
17 inhibitor
18 nausea
19 neurokinin
20 non small cell lung cancer
21 patient
22 placebo
23 placebo group
24 plasma
25 plasma concentration
26 platinum-based chemotherapy
27 prevention
28 same dose
29 side effect
30 vomiting
31 schema:name Randomized Phase 3 Study of Aprepitant Versus Placebo in Chinese Advanced Non-small Cell Lung Cancer Who Received Highly Emetogenic Chemotherapy
32 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT02161991
33 schema:sdDatePublished 2019-03-07T15:25
34 schema:sdLicense https://scigraph.springernature.com/explorer/license/
35 schema:sdPublisher N755a07bd57e04fb8b808472f5736ab6f
36 schema:sponsor https://www.grid.ac/institutes/grid.410622.3
37 schema:startDate 2014-06-01T00:00:00Z
38 schema:subjectOf sg:pub.10.1007/s00520-013-2043-9
39 https://doi.org/10.1016/j.bbmt.2012.07.019
40 https://doi.org/10.1016/j.ctrv.2012.09.002
41 https://doi.org/10.1200/jco.2011.39.5558
42 schema:url https://clinicaltrials.gov/show/NCT02161991
43 sgo:license sg:explorer/license/
44 sgo:sdDataset clinical_trials
45 rdf:type schema:MedicalStudy
46 N755a07bd57e04fb8b808472f5736ab6f schema:name Springer Nature - SN SciGraph project
47 rdf:type schema:Organization
48 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
49 rdf:type schema:DefinedTerm
50 sg:pub.10.1007/s00520-013-2043-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004661795
51 https://doi.org/10.1007/s00520-013-2043-9
52 rdf:type schema:CreativeWork
53 https://doi.org/10.1016/j.bbmt.2012.07.019 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019208035
54 rdf:type schema:CreativeWork
55 https://doi.org/10.1016/j.ctrv.2012.09.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038011325
56 rdf:type schema:CreativeWork
57 https://doi.org/10.1200/jco.2011.39.5558 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025698429
58 rdf:type schema:CreativeWork
59 https://www.grid.ac/institutes/grid.410622.3 schema:Organization
 




Preview window. Press ESC to close (or click here)


...